Multicenter Phase II Study of FOLFOX Plus Bi-weekly Cetuximab as First Line Treatment in Patients with Metastatic Colorectal Cancer
Not Applicable
- Conditions
- Metastatic Colorectal Cancer
- Registration Number
- JPRN-UMIN000006402
- Lead Sponsor
- Epidemiological and Clinical Research Information Network
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 55
Inclusion Criteria
Not provided
Exclusion Criteria
No serious myelosuppression 2)No sensory alteration or paresthesia interfering with function 3)No mental disease or neurovascular disease 4)No radiotherapy to target lesion 5)No severe stenosis by primary lesion 6)No hypersensitivity for test drugs 7)No serious infection 8)No cardiovascular disease, complication 9)No brain metastasis, 10)No large quantity of abdominal or pleural effusion 11)No diarrhea, 12)No active double cancer
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method